LITZMAN, Jiří, Marcela KREJČÍ, Sáva PEŠÁK and Jindřich LOKAJ. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency. Scripta Medica (Brno). Brno: LF MU Brno, 1999, vol. 72, No 4, p. 115-124. ISSN 1211-3395.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T-lymphocyte immunodeficiency
Authors LITZMAN, Jiří (203 Czech Republic, guarantor), Marcela KREJČÍ, Sáva PEŠÁK (203 Czech Republic) and Jindřich LOKAJ (203 Czech Republic).
Edition Scripta Medica (Brno), Brno, LF MU Brno, 1999, 1211-3395.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30209 Paediatrics
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/99:00003614
Organization unit Faculty of Medicine
Keywords in English inosine pranobex; immunodeficiency; immunotherapy
Tags immunodeficiency, Immunotherapy, Inosine pranobex
Changed by Changed by: prof. MUDr. Jiří Litzman, CSc., učo 403. Changed: 22/6/2009 16:09.
Abstract
Isoprinosine is a T-lymphocyte enhancing agent sometimes recommended for the treatment of patients with T-lymphocyte deficiency and clinical signs of immunodeficiency. We performed a double-blind trial of treatment of children aged 4-8 years with frequent respiratory tract infection and laboratory signs of T-lymphocyte deficiency - decreased absolute or relative numbers of E-rosette forming cells, CD3+ and CD4+ lymphocytes or increased numbers of CD8+ cells. Thirty two children that finished the study were given isoprinosine and 25 placebo. We could not show any clinical benefit of the administration of isoprinosine on the frequency or severity of respiratory tract infections compared to placebo. An increase in the number of E-rosette forming cells, CD4+ and CD3+ lymphocytes was observed after 6 weeks of isoprinosine administration, but similar, although not significant, changes were observed in the placebo treated group.
Links
NI4703, research and development projectName: Poruchy imunoregulace u nemocných s humorálními imunodeficity
Investor: Ministry of Health of the CR, Immunoregulatory defects in patients with humoral immunodeficiencies
PrintDisplayed: 13/7/2024 12:42